Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway.

MLA

Pera, Benet, et al. “Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway.” EBioMedicine, vol. 28, Feb. 2018, pp. 80–89. EBSCOhost, https://doi.org/10.1016/j.ebiom.2018.01.014.

APA

Pera, B., Krumsiek, J., Assouline, S. E., Marullo, R., Patel, J., Phillip, J. M., Román, L., Mann, K. K., & Cerchietti, L. (2018). Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway. EBioMedicine, 28, 80–89. https://doi.org/10.1016/j.ebiom.2018.01.014

Chicago

Pera, Benet, Jan Krumsiek, Sarit E Assouline, Rossella Marullo, Jayeshkumar Patel, Jude M Phillip, Lidia Román, Koren K Mann, and Leandro Cerchietti. 2018. “Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway.” EBioMedicine 28 (February): 80–89. doi:10.1016/j.ebiom.2018.01.014.